Birch triterpenes by Chiesi Farmaceutici for Radiodermatitis: Likelihood of Approval

Birch triterpenes is under clinical development by Chiesi Farmaceutici and currently in Phase II for Radiodermatitis.

Buck Institute receives $3.5 million federal grant to lead clinical trial of ketone intervention in older adults

The Buck Institute for Research on Aging has received a $3.5 million federal grant to lead the first-ever double-blind, randomized, placebo-controlled clinical trial to understand

September 11, 2023

PocketHealth Unveils Appointment Reminders to Enhance Patent Engagement

What You Should Know: PocketHealth today launched Appointment Reminders, a new product integrated within its image sharing platform that enables healthcare providers to reduce the number

July 27, 2023

Autoimmune Afib; Inappropriate ICD Shocks Down; Dissolving Cardiac Sensors

FDA approved expanded use of inclisiran (Leqvio) for primary hyperlipidemia atop its existing indications of atherosclerotic cardiovascular and heterozygous familial hypercholesterolemia, Novartis announced. An estimate

July 12, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.